Liver and biliary tract cancer: trials for referral
1508 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Liver and biliary tract cancer·What we know·Glossary·Tumour board sheet
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 1508 open trials.
Phase 21 site
Not yet recruitingUnited States
NCT07793253
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 237 sites
RecruitingGermany, Spain, France, United Kingdom, Italy, Taiwan
NCT07219459
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
CatalYm GmbH
Pre-treatment window Registry sentence: “More than 1 line of prior systemic treatment for unresectable or metastatic HCC.”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 32 sites
RecruitingAustralia, New Zealand
NCT07836530
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
BeOne Medicines
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
Not yet recruitingUnited States
NCT07715903
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
National Cancer Institute (NCI)
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/222 sites
RecruitingAustralia, Spain, France, United States
NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 24 sites
RecruitingChina
NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
Haibo Shao
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT06066138
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Cancer Institute (NCI)
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govNo phase2 sites
RecruitingUnited Kingdom
NCT06434493
Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
The Christie NHS Foundation Trust
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 219 sites
RecruitingSpain, France, United Kingdom, South Korea, United States
NCT07359820
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Elevar Therapeutics
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govNo phase46 sites
RecruitingUnited States
NCT06995898
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase6 sites
RecruitingUnited States
NCT07817147
CREO - Microwave Ablation Feasibility Study
Banner Health
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingChina
NCT07919717
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
Shanghai Zhongshan Hospital
Pre-treatment window Registry sentence: “Subjects must have at least one previously untreated lesion that is measurable according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).”
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT06855225
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Mehmet Akce
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 35 sites
RecruitingTaiwan, United States
NCT06622057
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
InnoPharmax Inc.
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingChina
NCT07916870
Photodynamic Therapy Combined With a Self-expandable Radioactive Particle-loaded Biliary Stent for Unresectable Extrahepatic Cholangiocarcinoma
Zhai Wenlong
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 254 sites
RecruitingAustralia, Canada, Switzerland, China, Denmark, Spain
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 129 sites
RecruitingChina, Germany, Japan, Netherlands, United States
NCT07213791
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 31 site
Not yet recruitingChina
NCT07916844
Hepatic Arterial Infusion Chemotherapy Versus Capecitabine as Adjuvant Therapy for Resected Biliary Tract Cancer
Zhai Wenlong
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07917481
A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma
MedSIR
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07433673
Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Columbia University
Pre-treatment window Registry sentence: “Treatment naïve; no prior systemic therapy”
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07827807
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
Chang Gung Memorial Hospital
Pre-treatment window Registry sentence: “Prior systemic therapy for HCC”
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 1/22 sites
RecruitingUnited States
NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
VM Discovery, Inc.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 20 sites
Not yet recruiting
NCT07911683
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
BeOne Medicines
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingTaiwan
NCT07908550
Daraxonrasib in Asian RAS-mutant Biliary Tract Cancer
National Health Research Institutes, Taiwan
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingUnited States
NCT07909031
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingUnited States
NCT07723534
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
Midhun Malla
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT07766187
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
University of Wisconsin, Madison
Pre-treatment window Registry sentence: “Index Tumor will be a predetermined non-histotripsy tumor in patients with multifocal disease, or a predetermined region of intentionally untreated tumor in patients with solitary disease.”
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingUnited States
NCT07430202
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT05849480
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
National Cancer Institute (NCI)
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 2/31 site
RecruitingChina
NCT07589244
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Guangzhou Virotech Pharmaceutical Co., Ltd.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States164 open trials
- China154 open trials
- Spain33 open trials
- South Korea33 open trials
- Taiwan32 open trials
- France31 open trials
- Australia31 open trials
- Italy25 open trials
- Japan25 open trials
- Germany23 open trials
- United Kingdom22 open trials
- Canada19 open trials
- Netherlands13 open trials
- Poland11 open trials
- Belgium8 open trials
- Türkiye7 open trials
- Brazil7 open trials
- Singapore7 open trials
- Hong Kong7 open trials
- Puerto Rico6 open trials
- Switzerland5 open trials
- Israel5 open trials
- Chile4 open trials
- Portugal4 open trials
- India4 open trials
- Thailand4 open trials
- New Zealand3 open trials
- Argentina3 open trials
- Sweden3 open trials
- Ireland3 open trials
- Czechia2 open trials
- Romania2 open trials
- Finland2 open trials
- Vietnam2 open trials
- Malaysia2 open trials
- Austria2 open trials
- Georgia2 open trials
- Denmark1 open trial
- Serbia1 open trial
- Mexico1 open trial
- Slovakia1 open trial
- Philippines1 open trial
- Saudi Arabia1 open trial
- Egypt1 open trial
- Moldova1 open trial
- Norway1 open trial
- Iran1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Cancer Hospital of Chinese Academy of Medical Sciences
Beijing, China
21 trials · 101 publications · ROR
First Affiliated Hospital of GuangXi Medical University
Nanning, China
9 trials · 159 publications · ROR
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China
13 trials · 88 publications · ROR
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
18 trials · 127 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Anatomic Versus Nonanatomic Liver Resection After Conversion Therapy for Hepatocellular Carcinoma
NCT07927452 · No phase · China
Source: ClinicalTrials.govOpened for recruitment
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
NCT07836530 · Phase 3 · Australia, New Zealand
Source: ClinicalTrials.govOpened for recruitment
Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
NCT06434493 · No phase · United Kingdom
Source: ClinicalTrials.govNew in the registry
INPACT: Implementation of Nutritional Support and Physical Activity During Cancer Treatment
NCT07929597 · No phase · Belgium
Source: ClinicalTrials.govPhase changed: No phase → Phase 1/2
Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN
NCT06735560 · Phase 1/2 · France
Source: ClinicalTrials.govNew in the registry
Composition for Treating Cirrhosis and Liver Cancer (SB-1121)
NCT05178303 · Phase 4 · Vietnam
Source: ClinicalTrials.govClosed for recruitment
Pathological and Clinical Features of Patients Treated With ATZ+BEV in Romania
NCT06903663 · No phase · Romania
Source: ClinicalTrials.govStatus changed: Running, not recruiting → Completed
WISH for Treatment Selection and Survival Prediction in Unresectable Hepatocellular Carcinoma
NCT07065786 · No phase · China
Source: ClinicalTrials.govNew in the registry
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
NCT07919717 · Phase 2 · China
Source: ClinicalTrials.govStopped early
CT-95 in Advanced Cancers Associated With Mesothelin Expression
NCT06756035 · Phase 1 · United States
Source: ClinicalTrials.govOpened for recruitment
NCT07227012 · Phase 1/2 · China, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govPhase changed: Phase 2/3 → Phase 2
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
NCT07128290 · Phase 2 · France
Source: ClinicalTrials.gov
Show more
Status changed: Running, not recruiting → Not yet recruiting
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
NCT07128290 · Phase 2 · France
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
NCT06984718 · Phase 2 · Spain, France, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022 · Phase 1/2 · China, Spain, Hong Kong, Japan, South Korea, Taiwan
Source: ClinicalTrials.govOpened for recruitment
NCT06858813 · Phase 1 · China, Spain, Israel, Japan, Puerto Rico, Taiwan
Source: ClinicalTrials.govClosed for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567 · Phase 1/2 · Czechia, Germany, Denmark, Spain, France, Italy
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941 · Phase 2 · Australia, Canada, China, Spain, United Kingdom, Georgia
Source: ClinicalTrials.govOpened for recruitment
NCT06282575 · Phase 3 · Argentina, Belgium, Brazil, Canada, Chile, China
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05904886 · Phase 3 · Belgium, Brazil, Canada, Côte d’Ivoire, China, Germany
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05901194 · Phase 1/2 · France
Source: ClinicalTrials.govOpened for recruitment
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176 · Phase 2 · Argentina, Australia, Brazil, Canada, China, Spain
Source: ClinicalTrials.govClosed for recruitment
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
NCT05622071 · Phase 2 · France
Source: ClinicalTrials.govOpened for recruitment
Durvalumab and Tremelimumab in Resectable HCC
NCT05440864 · Phase 2 · Canada, Spain, Italy
Source: ClinicalTrials.govOpened for recruitment
NCT04803994 · Phase 3 · Austria, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC
NCT04523493 · Phase 3 · China, Italy, Poland, Singapore, Ukraine
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04238637 · Phase 2 · Germany, Spain
Source: ClinicalTrials.govClosed for recruitment
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797 · Phase 1/2 · Canada, China, Denmark, Spain, France, Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT03778957 · Phase 3 · Australia, Brazil, Canada, China, Spain, France
Source: ClinicalTrials.govClosed for recruitment
NCT03847428 · Phase 3 · Austria, Australia, Brazil, Canada, China, Germany
Source: ClinicalTrials.govClosed for recruitment
Paediatric Hepatic International Tumour Trial
NCT03017326 · Phase 3 · Austria, Belgium, Switzerland, Czechia, Germany, Spain
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT02170090 · Phase 3 · Austria, Australia, Germany, Denmark, United Kingdom, Italy
Source: ClinicalTrials.govClosed for recruitment
NCT06282575 · Phase 3 · Argentina, Belgium, Brazil, Canada, Chile, China
Source: ClinicalTrials.govClosed for recruitment
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176 · Phase 2 · Argentina, Australia, Brazil, Canada, China, Spain
Source: ClinicalTrials.govClosed for recruitment
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
NCT07128290 · Phase 2 · France
Source: ClinicalTrials.govOpened for recruitment
NCT03847428 · Phase 3 · Austria, Australia, Brazil, Canada, China, Germany
Source: ClinicalTrials.govOpened for recruitment
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
NCT05622071 · Phase 2 · France
Source: ClinicalTrials.govClosed for recruitment
NCT04803994 · Phase 3 · Austria, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govClosed for recruitment
Durvalumab and Tremelimumab in Resectable HCC
NCT05440864 · Phase 2 · Canada, Spain, Italy
Source: ClinicalTrials.govOpened for recruitment
Paediatric Hepatic International Tumour Trial
NCT03017326 · Phase 3 · Austria, Belgium, Switzerland, Czechia, Germany, Spain
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
NCT06795022 · Phase 1/2 · China, Spain, Hong Kong, Japan, South Korea, Taiwan
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07227012 · Phase 1/2 · China, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govOpened for recruitment
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
NCT06984718 · Phase 2 · Spain, France, Italy, Poland
Source: ClinicalTrials.govOpened for recruitment
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797 · Phase 1/2 · Canada, China, Denmark, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govClosed for recruitment
NCT06858813 · Phase 1 · China, Spain, Israel, Japan, Puerto Rico, Taiwan
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy
Source: ClinicalTrials.govNew in the registry
Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response
NCT07916376 · No phase · United States
Source: ClinicalTrials.gov
New reviews, guidelines and randomised trials in PubMed
Systematic review
Frontiers in oncology · PubMed
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 1Ended 3 Nov 2026
Stopped early53 participants
NCT05075993
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Reason given: \<75% participation
No phaseEnded 31 Oct 2026
Completed4798 participants
NCT07065786
WISH for Treatment Selection and Survival Prediction in Unresectable Hepatocellular Carcinoma
Phase 3Ended 20 Oct 2026
No phaseEnded 14 Oct 2026
Phase 1Ended 9 Oct 2026
Stopped early19 participants
NCT06756035
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Reason given: The study was halted prematurely and will not resume; participants are no longer receiving intervention or undergoing evaluations. The termination was not due to any safety or efficacy concerns.
No phaseEnded 8 Oct 2026
Completed243 participants
NCT07091942
Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
No phaseEnded 2 Oct 2026
Stopped early23 participants
NCT07178093
Effects of Antrodia Cinnamomea on the Hepatoma Patients After Transcatheter Hepatic Artery Chemoembolization
Reason given: poor accrual and insufficient drug supply
Phase 2Ended 30 Sept 2026
Stopped early73 participants
NCT05879822
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Reason given: This was a strategic business decision. There were no safety concerns contributing to this decision.
Phase 1Ended 30 Sept 2026
Completed11 participants
NCT06374485
Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment
No phaseEnded 29 Sept 2026
Completed132 participants
NCT06549829
the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma
Phase 3Ended 28 Sept 2026
Completed145 participants
2023-508726-10-00
A Phase 3 Study of Nivolumab versus Placebo for Participants with Hepatocellular Cancer Who Are at High Risk of Recurrence after Hepatic Resection or Ablation
No phaseEnded 26 Sept 2026
Phase 4Ended 23 Sept 2026
Completed657 participants
NCT05971108
Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC
Phase 1Ended 18 Sept 2026
Stopped early3 participants
NCT06487559
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
Reason given: Strategic considerations
No phaseEnded 31 Aug 2026
Completed20 participants
NCT04868149
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
No phaseEnded 31 Aug 2026
Completed2527 participants
NCT06790355
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
Phase 2Ended Aug 2026
Withdrawn before start0 participants
NCT04796454
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
Reason given: Company decision
No phaseEnded 30 Aug 2026
Phase 1Ended 26 Aug 2026
No phaseEnded 15 Aug 2026
Completed60 participants
NCT07642336
Erector Spinae Plane Block Versus Thoracic Epidural Analgesia for Open Liver Resection
Show more
Phase 1/2Ended 14 Aug 2026
Withdrawn before start0 participants
NCT03812874
A Study of PTX-9908 Injection for Non-resectable HCC With TACE
Reason given: Due to business considerations and challenges in participant recruitment, the Sponsor has decided to discontinue the study.
Phase 3Ended 10 Aug 2026
Phase 2/3Ended 9 Aug 2026
No phaseEnded 6 Aug 2026
Completed132 participants
NCT04145141
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
Early Phase 1Ended 3 Aug 2026
Completed20 participants
NCT03143270
A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer
Early Phase 1Ended 31 Jul 2026
Withdrawn before start0 participants
NCT06572189
The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma
Reason given: Based on the results of another intravenous injection therapy CD-801 for the treatment of hepatocellular carcinoma, we have decided to change the administration method and therefore withdraw this trial protocol.
No phaseEnded 31 Jul 2026
Completed2756 participants
NCT03782207
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Phase 1Ended 31 Jul 2026
No phaseEnded 30 Jul 2026
Completed251 participants
NCT06248554
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
Phase 3Ended 27 Jul 2026
Completed908 participants
NCT03847428
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
No phaseEnded 23 Jul 2026
Completed120 participants
NCT07745153
Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors
No phaseEnded 20 Jul 2026
Completed26 participants
NCT05563870
Endoscopy and Radiology-guided Ablation for Inoperable Cholangiocarcinoma
No phaseEnded 16 Jul 2026
Phase 1Ended 16 Jul 2026
Completed138 participants
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Phase 2Ended 13 Jul 2026
Phase 3Ended 9 Jul 2026
Completed732 participants
NCT04039607
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer). · Future oncology (London, England), 2026
Phase 1Ended 8 Jul 2026
Completed27 participants
NCT06399757
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 2Ended 7 Jul 2026
Completed52 participants
NCT02968810
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
Phase 2Ended 1 Jul 2026
Completed128 participants
NCT06114082
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients With Hepatocellular Carcinoma
No phaseEnded 30 Jun 2026
Completed48 participants
NCT07704021
Safety and Efficacy of EUS-guided Gallbladder Drainage Under Endoscopist-directed Conscious Sedation
Phase 2Ended 30 Jun 2026
Paused34 participants
NCT06199882
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Reason given: Patient recruitment difficulties
Phase 2Ended 29 Jun 2026
Completed30 participants
NCT04294498
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
Phase 1Ended 22 Jun 2026
Phase 2Ended 16 Jun 2026
Completed104 participants
2023-503905-12-00
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors
Phase 1/2Ended 15 Jun 2026
Stopped early2 participants
NCT05435014
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
Reason given: T-ACE Medical Co., Ltd. hereby submits this formal notification to the U.S. Food and Drug Administration (FDA) to request the permanent discontinuation and withdrawal of Investigational New Drug application IND 152626.
No phaseEnded 10 Jun 2026
Completed20 participants
NCT04892810
Immunomonitoring of Interventional Radiology Procedures in the Management of Hepatocellular Carcinoma
Phase 1Ended 10 Jun 2026
Stopped early36 participants
NCT02626312
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
Reason given: \< 75% participation
- Single-photon emission computed tomography functional liver imaging to facilitate reirradiation for liver malignancies: A phase I trial. · JHEP reports : innovation in hepatology, 2026
No phaseEnded 31 May 2026
Phase 1/2Ended 30 May 2026
Completed49 participants
NCT05742750
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
No phaseEnded 29 May 2026
Completed178 participants
NCT06903663
Pathological and Clinical Features of Patients Treated With ATZ+BEV in Romania
No phaseEnded 28 May 2026
Phase 2Ended 26 May 2026
Completed40 participants
NCT04954339
DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab
No phaseEnded 21 May 2026
Completed40 participants
NCT05874934
Endoscopic Drainage of Presumed Resectable pCCA Using an Intrahepatic Plastic Stent With Retrieval String
Phase 3Ended 15 May 2026
Completed668 participants
NCT04102098
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
- Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. · Journal of hepatology, 2026
Phase 2Ended 8 May 2026
No phaseEnded 30 Apr 2026
Completed3650 participants
NCT05540925
Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma
Phase 2Ended 30 Apr 2026
Completed78 participants
NCT04930315
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma
Phase 2Ended 24 Apr 2026
Completed35 participants
2023-503341-60-00
Efficacy evaluation of 188Re-SSS lipiodol Selective Internal Radiation Therapy of non operable hepatocellular carcinoma patients, a phase II study
Phase 2Ended 24 Apr 2026
Stopped early16 participants
NCT05797870
Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)
Reason given: The last visit of the last patient was done.
Phase 2Ended 21 Apr 2026
Completed90 participants
2024-516737-12-00
A trial to learn how well NMS-01940153E works in combination with atezolizumab and priming administration of decitabine or with atezolizumab alone in patients with hepatocellular carcinoma (HCC) that cannot be removed by surgery and who received prior treatment with other anti-cancer medicines
Not medical advice. fetched 12 Nov 2026